Vertex Pharmaceuticals Inc / Ma (VRTX) Stock Price & Analysis
Vertex Pharmaceuticals Inc / Ma (VRTX) rose 0.63% to USD 445.77 as of June 9, 2026 at 22:38 UTC, according to Nexqual real-time market data.
VRTX last closed at USD 442.96; the session ranged USD 441.2–449.5 on volume of 870,795 shares. Market capitalization is $113.14B, with a 52-week range of USD 362.5–507.92 (NMS). Source: Nexqual, June 9, 2026 at 22:38 UTC.
Key Statistics (as of June 9, 2026 at 22:38 UTC)
| Price | USD 445.77 |
|---|---|
| Change | ▲ 0.63% (up) |
| Previous Close | USD 442.96 |
| Open | USD 447.02 |
| Day Range | USD 441.2 – 449.5 |
| 52-Week Range | USD 362.5 – 507.92 |
| Volume | 870,795 shares |
| Market Cap | $113.14B |
| Exchange | NMS |
Technical Analysis (VRTX)
Nexqual's technical model rates VRTX "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 9, 2026 at 22:38 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 54.74 (neutral) |
| vs SMA50 | Above (USD 436.98) |
| MACD | 1.27 (positive) |
Analyst Ratings (VRTX)
Wall Street analysts rate VRTX "Buy" based on 29 analysts, with a mean price target of USD 548.69 (range USD 330–641), per Nexqual as of June 9, 2026 at 22:38 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 29 |
| Mean Target | USD 548.69 |
| High Target | USD 641 |
| Low Target | USD 330 |
| Buy / Hold / Sell | 27 / 5 / 1 |
Earnings (VRTX)
| Next Earnings Date | 2026-08-03 |
|---|---|
| EPS Estimate | USD 4.73 |
| Revenue Estimate | $3.21B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 4.47 vs est 4.31 ▲ beat |
| 2025-12-31 | USD 5.03 vs est 5.15 ▼ miss |
| 2025-09-30 | USD 4.8 vs est 4.58 ▲ beat |
| 2025-06-30 | USD 4.52 vs est 4.25 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:38 UTC.
Financials & Fundamentals (VRTX)
| Total Revenue | $12.22B |
|---|---|
| Revenue Growth (YoY) | +7.80% |
| Gross Margin | +54.39% |
| Operating Margin | +38.13% |
| Profit Margin | +35.51% |
| ROE | +24.20% |
| Debt / Equity | 10.26 |
| Current Ratio | 3.02 |
| Total Cash | $7.25B |
| Total Debt | $1.99B |
| Free Cash Flow | $2.78B |
Source: Nexqual, June 9, 2026 at 22:38 UTC.
Financial Health Score (VRTX)
Nexqual rates Vertex Pharmaceuticals Inc / Ma's overall financial health "Strong" across five dimensions, as of June 9, 2026 at 22:38 UTC.
| Growth | Solid — Revenue +9% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 54%, operating 38% |
| Balance Sheet | Strong — $7.25B cash vs $1.99B debt, net cash position |
| Cash Flow | Strong — FCF $2.78B, 23% margin |
| Efficiency | Strong — ROE 24%, ROA 12.1% |
Ownership (VRTX)
| Insider Ownership | +0.20% |
|---|---|
| Institutional Ownership | +98.03% |
| Shares Outstanding | 253.81M |
| Float | 253.02M |
| Short % of Float | +1.99% |
Source: Nexqual, June 9, 2026 at 22:38 UTC.
Leadership (VRTX)
Vertex Pharmaceuticals Inc / Ma is led by Reshma Kewalramani FASN (age 52), CEO, President & Director, per Nexqual as of June 9, 2026 at 22:38 UTC.
| CEO, President & Director | Reshma Kewalramani FASN (age 52) |
|---|---|
| Executive Chairman | Jeffrey Marc Leiden (age 69) |
| Executive VP, COO & CFO | Charles F. Wagner (age 57) |
| Executive VP & Chief Scientific Officer | Mark Bunnage D.Phil (age 56) |
| Senior Vice President of Investor Relations | Susie Lisa C.F.A. |
Major Backers & Investors (VRTX)
Notable institutional backers of Vertex Pharmaceuticals Inc / Ma include Capital Group, GROWTH FUND OF AMERICA, JPMorgan, according to Nexqual as of June 9, 2026 at 22:38 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capital Group | 18.32% |
| GROWTH FUND OF AMERICA | 5.49% |
| JPMorgan | 2.77% |
| INVESTMENT CO OF AMERICA | 2.47% |
| AMERICAN BALANCED FUND | 2.34% |
| Invesco | 2.14% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 14.26% |
| BlackRock | 10.73% |
| State Street | 4.62% |
| Geode Capital | 2.42% |
Source: Nexqual, June 9, 2026 at 22:38 UTC.
From Vertex Pharmaceuticals Inc / Ma's Latest SEC 10-K Filing (filed 2026-02-13)
Key Strengths & Strategy (as disclosed to the SEC)
- Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally.
- The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain.
- It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor.
- The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| REGN | Regeneron Pharmaceuticals, Inc. | USD 616.18 | ▼ 3.03% |
| BIIB | Biogen Inc. | USD 199.1 | ▲ 1.92% |
| INCY | Incyte Corporation | USD 103.23 | ▲ 0.83% |
| ILMN | Illumina, Inc. | USD 160.03 | ▼ 1.41% |
| BMRN | BioMarin Pharmaceutical Inc. | USD 57.91 | ▲ 2.01% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:38 UTC. This page is informational and not investment advice.